Tazemetostat Receives FDA Priority Overview for Metastatic or Locally Sophisticated Epithelioid Sarcoma
[ad_1] A new drug application (NDA) for tazemetostat, an EZH2 inhibitor, has been granted a priority evaluation by the FDA for the therapy of sufferers with metastatic or locally sophisticated epithelioid […]
